A recent study led by Dr Ed Jabbari and part funded by PSPA, has shown promise in distinguishing PSP from Parkinson’s.
The study, which has been published in the Lancet journal, highlights the potential of a biomarker test (α-synuclein SAA) for earlier, more accurate diagnosis of Parkinson’s and similar conditions like PSP & CBD.
In the paper you can read about how this biomarker test can:
– Distinguish Parkinson’s from similar conditions like progressive supranuclear palsy.
– Predict cognitive decline in patients.
This breakthrough could lead to better treatments and improved trial design!
Read a summary of the paper, here.
